Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction
Restricted accessResearch articleFirst published online January, 2019
Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction
We assessed the prevalence of newly diagnosed prediabetes and type-2 diabetes mellitus (T2DM), and their impact on long-term mortality in patients hospitalized for worsening heart failure with reduced ejection fraction (HFrEF).
Methods
We included patients hospitalized with HFrEF and New York Heart Association (NYHA) functional class II–III. Baseline two-hour oral glucose tolerance test was used to classify patients as normoglycaemic or having newly diagnosed prediabetes or T2DM. Outcomes included post-discharge all-cause and cardiovascular mortality during the median follow-up of 2.1 years.
Results
At baseline, out of 150 patients (mean-age 57 ± 12 years; 88% male), prediabetes was diagnosed in 65 (43%) patients, and T2DM in 29 (19%) patients. These patients were older and more often with NYHA class III symptoms, but distribution of comorbidities was similar to normoglycaemic patients. Taking normoglycaemic patients as a reference, adjusted risk of all-cause mortality was significantly increased both in patients with prediabetes (hazard ratio, 2.6; 95% confidence interval (CI), 1.1–6.3; p = 0.040) and in patients with T2DM (hazard ratio, 5.3; 95% CI, 1.7–15.3; p = 0.023). Likewise, both prediabetes (hazard ratio, 2.9; 95% CI, 1.1–7.9; p = 0.041) and T2DM (hazard ratio, 9.7; 95% CI 2.9–36.7; p = 0.018) independently increased the risk of cardiovascular mortality compared with normoglycaemic individuals. There was no interaction between either prediabetes or T2DM and heart failure aetiology or gender on study outcomes (all interaction p-values > 0.05).
Conclusions
Newly diagnosed prediabetes and T2DM are highly prevalent in patients hospitalized for worsening HFrEF and NYHA functional class II–III. Importantly, they impose independently increased long-term risk of higher all-cause and cardiovascular mortality.
BuiALHorwichTBFonarowGC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol2011; 8: 30–41.
2.
ChioncelOLainscakMSeferovicPMet al.Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail2017; 19: 1574–1585.
3.
EgstrupMSchouMGustafssonIet al.Oral glucose tolerance testing in an outpatient heart failure clinic reveals a high proportion of undiagnosed diabetic patients with an adverse prognosis. Eur J Heart Fail2011; 13: 319–326.
4.
KristensenSLJhundPSLeeMMYet al.Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovasc Drugs Ther2017; 31: 545–549.
5.
StevensALHansenDVandorenVet al.Mandatory oral glucose tolerance tests identify more diabetics in stable patients with chronic heart failure: A prospective observational study. Diabetol Metab Syndr2014; 6: 44–44.
6.
American Diabetes Association. 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018; 41 (Suppl 1): S86-S104.
7.
SarmaSMentzRJKwasnyMJet al.Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: Findings from the EVEREST trial. Eur J Heart Fail2013; 15: 194–202.
8.
PocockSJAritiCAMcMurrayJJet al.Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies. Eur Heart J2013; 34: 1404–1413.
9.
ThrainsdottirISAspelundTHardarsonTet al.Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study. Eur J Cardiovasc Prev Rehabil2005; 12: 465–471.
10.
JorgensenMEAnderssonCVasanRSet al.Characteristics and prognosis of heart failure with improved compared with persistently reduced ejection fraction: A systematic review and meta-analyses. Eur J Prev Cardiol2018; 25: 366–376.
11.
DaurizMTargherGTemporelliPLet al.Prognostic impact of diabetes and prediabetes on survival outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. J Am Heart Assoc2017; 6: e005156–e005156.
12.
KristensenSLPreissDJhundPSet al.Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: Insights from Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail2016; 9: e002560–e002560.
13.
GreenbergBHAbrahamWTAlbertNMet al.Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: A report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J2007; 154: 277.e1–e8.
14.
YancyCWLopatinMStevensonLWet al.Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol2006; 47: 76–84.
15.
PonikowskiPVoorsAAAnkerSDet al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J2016; 37: 2129–2200.
16.
PintoYMElliottPMArbustiniEet al.Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J2016; 37: 1850–1858.
17.
GalderisiMCosynsBEdvardsenTet al.Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: An expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging2017; 18: 1301–1310.
18.
CockcroftDWGaultMH. Prediction of creatinine clearance from serum creatinine. Nephron1976; 16: 31–41.
19.
American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018; 41(Suppl 1): S13–S27.
20.
RydenLGrantPJAnkerSDet al.ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J2013; 34: 3035–3087.
21.
PeduzziPConcatoJFeinsteinARet al.Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol1995; 48: 1503–1510.
22.
VittinghoffEMcCullochCE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol2007; 165: 710–718.
23.
SeferovicPMPetrieMCFilippatosGSet al.Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail2018; 20: 853–872.
24.
SuskinNMcKelvieRSBurnsRJet al.Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J2000; 21: 1368–1375.
25.
O’ConnorCMStarlingRCHernandezAFet al.Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med2011; 365: 32–43.
26.
TeerlinkJRVoorsAAPonikowskiPet al.Serelaxin in addition to standard therapy in acute heart failure: Rationale and design of the RELAX-AHF-2 study. Eur J Heart Fail2017; 19: 800–809.
27.
TargherGDaurizMLarocheCet al.In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: Results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail2017; 19: 54–65.
28.
KristensenSLJhundPSKoberLet al.Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. Eur J Heart Fail2015; 17: 169–176.
29.
SolomonSDDobsonJPocockSet al.Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007; 116: 1482–1487.
30.
Crespo-LeiroMGAnkerSDMaggioniAPet al.European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail2016; 18: 613–625.
31.
De BloisJSimardSAtarDet al.COPD predicts mortality in HF: The Norwegian Heart Failure Registry. J Card Fail2010; 16: 225–229.
32.
KamaleshMSubramanianUSawadaSet al.Decreased survival in diabetic patients with heart failure due to systolic dysfunction. Eur J Heart Fail2006; 8: 404–408.
33.
DomanskiMKrause-SteinraufHDeedwaniaPet al.The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol2003; 42: 914–922.
34.
DriesDLSweitzerNKDraznerMHet al.Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol2001; 38: 421–428.
35.
GustafssonIBrendorpBSeibaekMet al.Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol2004; 43: 771–777.
36.
TargherGDaurizMTavazziLet al.Prognostic impact of in-hospital hyperglycemia in hospitalized patients with acute heart failure: Results of the IN-HF (Italian Network on Heart Failure) Outcome registry. Int J Cardiol2016; 203: 587–593.
37.
AnderssonCWeekePPeciniRet al.Long-term impact of diabetes in patients hospitalized with ischemic and non-ischemic heart failure. Scand Cardiovasc J2010; 44: 37–44.
38.
SeferovicPMPaulusWJ. Clinical diabetic cardiomyopathy: A two-faced disease with restrictive and dilated phenotypes. Eur Heart J2015; 36: 1718–1727, 27a-27c.
39.
PiepoliMFHoesAWAgewallSet al.2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol2016; 23: Np1–Np96.
40.
KnowlerWCBarrett-ConnorEFowlerSEet al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002; 346: 393–403.
41.
BanksAZMentzRJStebbinsAet al.Response to exercise training and outcomes in patients with heart failure and diabetes mellitus: Insights from the HF-ACTION Trial. J Card Fail2016; 22: 485–491.
42.
Antunes-CorreaLMUeno-PardiLMTrevizanPFet al.The influence of aetiology on the benefits of exercise training in patients with heart failure. Eur J Prev Cardiol2017; 24: 365–372.
43.
SandriMViehmannMAdamsVet al.Chronic heart failure and aging – effects of exercise training on endothelial function and mechanisms of endothelial regeneration: Results from the Leipzig Exercise Intervention in Chronic heart failure and Aging (LEICA) study. Eur J Prev Cardiol2016; 23: 349–358.
44.
DoletskyAAndreevDGivertsIet al.Interval training early after heart failure decompensation is safe and improves exercise tolerance and quality of life in selected patients. Eur J Prev Cardiol2018; 25: 9–18.
45.
SeferovicJPClaggettBSeidelmannSBet al.Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: A post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol2017; 5: 333–340.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
